- Home
- WKC vs EWTX Comparison
WKC vs EWTX Comparison
Compare WKC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKC
- EWTX
- Stock Information
- Founded
- WKC 1984
- EWTX 2017
- Country
- WKC United States
- EWTX United States
- Employees
- WKC N/A
- EWTX N/A
- Industry
- WKC Oil Refining/Marketing
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- WKC Energy
- EWTX Health Care
- Exchange
- WKC Nasdaq
- EWTX Nasdaq
- Market Cap
- WKC 1.5B
- EWTX 1.5B
- IPO Year
- WKC N/A
- EWTX 2021
- Fundamental
- Price
- WKC $25.27
- EWTX $14.01
- Analyst Decision
- WKC Hold
- EWTX Buy
- Analyst Count
- WKC 5
- EWTX 9
- Target Price
- WKC $29.40
- EWTX $39.89
- AVG Volume (30 Days)
- WKC 726.9K
- EWTX 815.0K
- Earning Date
- WKC 10-23-2025
- EWTX 11-06-2025
- Dividend Yield
- WKC 3.15%
- EWTX N/A
- EPS Growth
- WKC N/A
- EWTX N/A
- EPS
- WKC N/A
- EWTX N/A
- Revenue
- WKC $38,747,200,000.00
- EWTX N/A
- Revenue This Year
- WKC N/A
- EWTX N/A
- Revenue Next Year
- WKC $2.16
- EWTX N/A
- P/E Ratio
- WKC N/A
- EWTX N/A
- Revenue Growth
- WKC N/A
- EWTX N/A
- 52 Week Low
- WKC $22.71
- EWTX $10.60
- 52 Week High
- WKC $31.71
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- WKC 38.17
- EWTX 46.14
- Support Level
- WKC $26.49
- EWTX $14.08
- Resistance Level
- WKC $25.93
- EWTX $15.16
- Average True Range (ATR)
- WKC 0.57
- EWTX 0.70
- MACD
- WKC -0.11
- EWTX -0.08
- Stochastic Oscillator
- WKC 7.66
- EWTX 15.35
About WKC World Kinect Corporation
World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. The company earns the majority of its revenue from the Aviation segment.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.